Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

1350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 30-day, randomized, open-label, 3-arm, parallel-group, multicenter study exploring efficacy of intensive rosuvastatin treatment peri-PCI in Chinese patients with NSTE-ACS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients

NCT02420899

Acute Coronary Syndrome

UNKNOWN NA

Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS

NCT01245803

Acute Coronary Syndrome Angioplasty

UNKNOWN PHASE4

Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

NCT00329160

Hypercholesteremia

COMPLETED PHASE4

Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI

NCT01646307

Focus of Study

UNKNOWN PHASE4

Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI

NCT02859480

Coronary Artery Disease Coronary Disease Cardiovascular Diseases

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non ST-segment elevated acute coronary syndrome(NSTE-ACS) is increasing rapidly, and is more frequent than ST-segment elevated acute coronary syndrome (STE-ACS) now. NSTE-ACS patients sent to early PCI procedure is large and increasing rapidly in China.Quite a few trials have focused on high loading dose statin before PCI to improve cardiovascular outcomes in ACS. In Asian, high loading dose statin therapy showed different outcome. Rosuvastatin (RSV) is one of the most potent statins.Nowadays, quite a few experts think ACS patients undergoing PCI not only need loading dose statin, but also post PCI intensive statin treatment is rather important. Chinese consensus and western guidelines recommend intensive statin treatment in these patients. However, Chinese consensus referred to the western study as there's no relevant intensive statin treatment peri-PCI study in China until now.

Thus this study is designed to explore the efficacy of intensive statin treatment peri-PCI (early loading dose-RSV 40 mg or 20mg before PCI and subsequent 20mg post PCI) in periprocedural myocardial injury and 30 days MACE reduction in Chinese NSTE-ACS patients and explore efficacy of 30-day RSV 20 mg post-PCI treatment in lipid profile, inflammatory factors compared with baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-ST-elevation Acute Coronary Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

40mg Rosuvastatin group

The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

The subjects will receive intensive Rosuvastatin before and after PCI

20mg Rosuvastatin group

The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

The subjects will receive intensive Rosuvastatin before and after PCI

no statin group

The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

The subjects will receive intensive Rosuvastatin before and after PCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin

The subjects will receive intensive Rosuvastatin before and after PCI

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rosuvastatin Calcium Tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-80 year old males and non-child-bearing period females.
2. Clinical diagnosed with NSTE-ACS, including unstable angina or non-ST-segment elevation myocardial infarction(NSTEMI).

* For unstable angina, the diagnose should meet all below:

Clinical onset features: angina for at least 20 min when resting; initial onset angina pectoris(new onset within one month) manifests spontaneous angina or labor angina (CCS grade II or III); Symptoms of original stable angina pectoris aggravate in one month and at least achieve CCS grade III (accelerated angina pectoris); angina onset within one month after MI.

ECG: At least twice in one month: ST depression or elevation \>0.1millivolt (mv) or T-wave inversion ≥0.2 mv in 2 or more contiguous electrocardiographic leads when onset and the ST-T changes recovered after remission of chest pain. Myocardial damage marker do not elevate or reach the MI diagnostic level.
* For NSTEMI, the diagnose should meet all below ischemia symptoms(ischemic chest pain lasting more than 30 min and cannot relief significantly by sub-lingual NTG) ECG change: new ST-T dynamic development (new or transient ST depression ≥0.1mv or T-wave inversion≥0.2mv).

Myocardial damage marker level is normal or elevated to the MI diagnostic level.
3. Received early (within 48 h) Percutaneous Coronary Intervention(PCI).
4. Should be statin- naïve(last 3 months).
5. Only receive drug-eluting stents.
6. Sign the Informed Consent Form(ICF)

Exclusion Criteria

Any of the following is regarded as a criterion for exclusion from the study:

1. Diagnosis as STEMI;
2. NSTE-ACS with high-risk features warranting emergency coronary angiography;
3. Receive only medical therapy or Coronary Artery Bypass Graft(CABG)
4. Active liver disease or dysfunction including agnogenic serum transaminase sustained elevation or higher than 3 times upper limit of normal(ULN);
5. Left ventricular ejection fraction\<30%;
6. Previous or current treatment with statins;
7. Patients with myopathy or serum creatine kinase \> 5 times the upper limit of normal not caused by myocardial injury;
8. Severe renal function damage (creatinine clearance rate\<30 ml/min);
9. Severe anemia (haemoglobin\< 6g/L);
10. Diagnosed with malignancy within 5 years;
11. Concurrent use ciclosporin；
12. Investigator evaluated as not appropriate for statins.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No